MedPath

THE ARMY, UNITED STATES DEPARTMENT OF

THE ARMY, UNITED STATES DEPARTMENT OF logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
1893-01-01
Employees
1K
Market Cap
-
Website
http://wrair-www.army.mil

Clinical Trials

87

Active:1
Completed:44

Trial Phases

4 Phases

Phase 1:3
Phase 3:3
Phase 4:8
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (69 trials with phase data)• Click on a phase to view related trials

Not Applicable
55 (79.7%)
Phase 4
8 (11.6%)
Phase 1
3 (4.3%)
Phase 3
3 (4.3%)

Examining the Most Effective Method to Reduce Running Ground Contact Time

Not Applicable
Active, not recruiting
Conditions
Healthy Runners
First Posted Date
2025-05-25
Last Posted Date
2025-05-25
Lead Sponsor
Keller Army Community Hospital
Target Recruit Count
30
Registration Number
NCT06988709
Locations
🇺🇸

Keller Army Community Hospital, West Point, New York, United States

Neurocognitive Ankle Training for Instability to Optimize Neuromusculoskeletal Outcomes (NATION)

Not Applicable
Not yet recruiting
Conditions
Chronic Ankle Instability
First Posted Date
2024-07-30
Last Posted Date
2025-04-04
Lead Sponsor
Womack Army Medical Center
Target Recruit Count
180
Registration Number
NCT06527287

Emovi 3D Knee Assessment Device Intervention for Operational Readiness

Not Applicable
Recruiting
Conditions
Patellofemoral Pain Syndrome
Patellofemoral Pain
First Posted Date
2024-07-24
Last Posted Date
2025-07-16
Lead Sponsor
Womack Army Medical Center
Target Recruit Count
180
Registration Number
NCT06517056
Locations
🇺🇸

Tripler Army Medical Center, Honolulu, Hawaii, United States

🇺🇸

Womack Army Medical Center, Fort Liberty, North Carolina, United States

Dynamic Muscular Electrical Stimulation Following Anterior Cruciate Ligament Reconstruction in Military Academy Cadets

Not Applicable
Recruiting
Conditions
Anterior Cruciate Ligament Injuries
First Posted Date
2024-04-02
Last Posted Date
2025-02-20
Lead Sponsor
Keller Army Community Hospital
Target Recruit Count
60
Registration Number
NCT06341868
Locations
🇺🇸

Keller Army Community Hospital, West Point, New York, United States

Weight Loss and Physical Fitness Following Pregnancy in Active Duty Women

Not Applicable
Recruiting
Conditions
Weight Loss
Postpartum Weight Retention
First Posted Date
2022-08-26
Last Posted Date
2024-05-20
Lead Sponsor
Tripler Army Medical Center
Target Recruit Count
74
Registration Number
NCT05518604
Locations
🇺🇸

Tripler Army Medical Center, Honolulu, Hawaii, United States

🇺🇸

Desmond Doss Health Clinic, Schofield Barracks, Hawaii, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 18
  • Next

News

60 Degrees Pharmaceuticals Seeks FDA MUMS Designation for First Oral Canine Babesiosis Treatment

60 Degrees Pharmaceuticals will submit a Minor Use Minor Species (MUMS) designation request to the FDA for tafenoquine to treat acute canine babesiosis in 2025.

Nyrada's NYR-BI03 Shows Promise in Traumatic Brain Injury and Begins Phase 1 Clinical Trial

• Nyrada's lead drug candidate NYR-BI03 demonstrated statistically significant neuroprotection in a preclinical model of penetrating traumatic brain injury, according to a collaborative study with the Walter Reed Army Institute of Research. • The company has commenced recruitment for a Phase 1 clinical trial to assess safety, tolerability, and pharmacokinetics of NYR-BI03, with final readouts expected in Q3 2025. • Previous preclinical studies showed NYR-BI03 rescued 42% of brain tissue in stroke models and provided 86% cardioprotection following myocardial ischemic-reperfusion injury, positioning it as a promising first-in-class treatment.

Dx&Vx Advances Ferritin-Based Universal Coronavirus Vaccine to Phase 2 Trials Following Promising Phase 1 Results

Dx&Vx has acquired global development rights from Stanford University for a ferritin-based virus-like particle universal coronavirus vaccine that demonstrated neutralizing antibody levels more than ten times higher than mRNA vaccines in animal studies.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.